Table 1.
Study | Total number | Median age (year) | Disease stage | Ethnicity | Criterion | Genotype distribution |
ORR | HR | ||
AA | AG | GG | ||||||||
Li et al., 2012 | 87 | 59.08 | III–IV | Asian | RECIST | 53 | 30 | 4 | Yes | NR |
Dong et al., 2012 | 564 | NR | III–IV | Asian | RECIST | 33 | 227 | 304 | NR | Yes |
Joerger et al., 2012 | 131 | 59.7 | IIIB–IV | Caucasian | WHO | 17 | 63 | 51 | Yes | Yes |
Zhou et al., 2011 | 111 | NR | IV | Asian | WHO | 6 | 34 | 71 | Yes | NR |
Yao et al., 2010 | 106 | 61 | IIIB–IV | Asian | RECIST | 5 | 41 | 60 | Yes | NR |
Qian et al., 2010 | 107 | NR | IIIB–IV | Asian | WHO | 59 | 40 | 8 | Yes | NR |
Ding et al., 2010 | 54 | 60 | IIIB–IV | Asian | WHO | 13 | 10 | 31 | Yes | NR |
Sun et al., 2009 | 87 | 59 | IV | Asian | WHO | 4 | 30 | 53 | Yes | NR |
Yao et al., 2009 | 108 | 61 | IIIB–IV | Asian | WHO | 5 | 43 | 60 | Yes | Yes |
Kalikaki et al., 2009 | 119 | 119 | IIIA/B–IV | Caucasian | RECIST | 10 | 76 | 33 | Yes | Yes |
Fan et al., 2008 | 81 | 62.9 | IIIB–IV | Asian | WHO | 4 | 32 | 45 | Yes | NR |
Liu et al., 2008 | 53 | 61 | I–IV | Asian | RECIST | 8 | 18 | 27 | NR | Yes |
Giachino et al., 2007 | 248 | 62 | IIIA–IV | Caucasian | RECIST | 119 | 100 | 29 | NR | Yes |
Gao et al., 2006 | 57 | 59 | II–IV | Asian | RECIST | 31 | 23 | 3 | Yes | NR |
de las Penas et al., 2006 | 135 | 62 | IIIB–IV | Caucasian | RECIST | 51 | 65 | 19 | NR | Yes |
Wang et al., 2004 | 105 | 56 | IIIB–IV | Asian | WHO | 53 | 42 | 10 | Yes | NR |
Gurubhagavatula et al., 2004 | 103 | 58 | IIIA–IV | Caucasian | RECIST | 51 | 42 | 10 | NR | Yes |
NR: no report; RECIST: response evaluation criteria in solid tumours; WHO: World Health Organization; ORR: overall response rate; HR: hazard ratio